Seer, Inc. (SEER) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Seer, Inc.'s filing signal turned positive.

Seer, Inc. is a life sciences company pioneering new methods to decode the proteome for improved human health, leveraging its proprietary engineered nanoparticle (NP) technology and the Proteograph Product Suite. This integrated solution, comprising consumable assays, an automation instrument, and data analysis software, provides researchers with unbiased, deep, rapid, and large-scale access to the proteome, enabling biological discovery previously considered impractical. The Proteograph aims to overcome the trade-offs of traditional proteomic approaches by offering peptide-level resolution, allowing for the detection of protein isoforms and post-translational modifications without reliance on predefined binding epitopes. Launched in May 2025, the Proteograph ONE assay and SP200 automation instrument offer a tenfold throughput improvement, processing over 1,000 samples weekly and generating dense, high-resolution datasets suitable for AI-driven discovery. The company has served over 190 customers across more than 20 countries since its 2021 commercial launch, facilitating population-scale studies involving tens of thousands of samples.

Revenue is primarily generated from the sale of the Proteograph Product Suite, which includes instruments and consumables, as well as from services related to proteomic data generation and analysis.